Dorzolamide/latanoprost

Drug Profile

Dorzolamide/latanoprost

Alternative Names: ALZ-1101

Latest Information Update: 12 Feb 2016

Price : $50

At a glance

  • Originator Alleanza Pharmaceuticals
  • Class Antiglaucomas; Antihypertensives; Eye disorder therapies; Prostaglandins; Small molecules; Sulfonamides; Thiophenes
  • Mechanism of Action Carbonic anhydrase inhibitors; Prostaglandin F2 alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Glaucoma; Ocular hypertension

Most Recent Events

  • 11 Feb 2016 No recent reports on development identified - Phase-II for Ocular hypertension in USA (Ophthalmic)
  • 11 Feb 2016 No recent reports on development identified - Phase-II for Glaucoma in USA (Ophthalmic)
  • 01 Jan 2014 Alleanza Pharmaceuticals completes a phase II trial in Glaucoma and Ocular hypertension in USA (NCT01896180)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top